Interview with Dr. Hernán González

Interview with Dr. Hernán González, about thyroid cancer and his Thyrogen project.

Chilean vaccine against respiratory virus begins tests in the United States with production of 20 thousand doses

Chilean vaccine against respiratory virus begins tests in the United States with production of 20 thousand doses

Human metapneumovirus is one of the most dangerous viruses in acute respiratory infections and currently has no specific treatment or vaccines to combat it.

Dr. Hernán González, winner of the 2019 Avonni Award

Dr. Hernán González, winner of the 2019 Avonni Award

Report on winners of the Avonni 2019 award.

Science and technology with social impact

Science and technology with social impact

More and more researchers are dedicated exclusively to applied science whose findings are improving the quality of life of people in Chile and the world.

The four most common diseases in Chile

ThyroidPrint: the test that identifies with high accuracy whether a thyroid nodule is benign or not

ThyroidPrint: the test that identifies with high accuracy whether a thyroid nodule is benign or not

In Chile, 40% of the adult population has a thyroid nodule, but most cases have no clinical significance.

Patents Map

All Patents

View patents

Patents Applied for

View patents

Patents Granted

View patents

Dr. Alexis Kalergis

"Human Metapneumovirus causes high morbidity in the population, especially in infants and the elderly." The severity of this virus is the second cause of childhood pneumonia. Our team has developed a safe and effective vaccine against this virus. This has shown excellent protection results in pre-clinical studies.We are currently carrying out the clinical studies necessary to bring this vaccine onto the market and reduce the impact of this disease in the Chilean and international population."

Research Line / Vaccines
Project:
Safe and effective vaccines against Human Metapneumovirus (hMPV)

Dra. Susan Bueno

"Diagnostic tests only detect viruses, they do not detect bacteria, nor do they report on the severity of inflammatory response and the severity of infection. All of this along with the high costs of current testing creates the challenge and opportunity to develop one test that detects the multiple infectious agents in the respiratory tract in a specific, sensitive and simultaneous way and that detects some gravity and prognosis parameters of the patient so the doctor may decide on the best treatment option.”

Research / Diagnostic Line
Project:
Immunological Tools to Detect Respiratory Pathogens

Dr. Carlos Fardella

"The development of this project has allowed us to generate a multidisciplinary knowledge platform in order to collaborate in solving the problem of the increasing incidence of metabolic diseases in our population and at a global level."

Research / Therapy Line
Project:
Development of new drugs for the treatment of hypertension and metabolic syndrome

Dr. Hernán González

"Globally, there are 600,000 cases of thyroid cancer annually. However, there is not one test to predict the aggressiveness of this illness in order to choose more precise treatments according to the patient's profile. After the development of a thyroid cancer diagnostic test - known as Thyrioprint - it was logical to follow up with a second test that could predict with high accuracy the biological behavior of the tumor. Knowing how aggressive the cancer is can change the definitive treatment of the profile of the patient prior to surgery.”

Research Line / Diagnostics
Project:
Thyroid Cancer Prognosis Test

Av. Libertador Bernardo O'Higgins 440, piso 12, Santiago, chile.

Phone: (56) 223541958 / Email: info@bmrc.cl